Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.33
-0.1200-4.90%
Post-market: 2.440.1126+4.83%19:59 EDT
Volume:1.70M
Turnover:4.07M
Market Cap:279.60M
PE:-2.21
High:2.51
Open:2.46
Low:2.32
Close:2.45
52wk High:3.23
52wk Low:0.9335
Shares:120.00M
Float Shares:104.94M
Volume Ratio:0.95
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.82
PE(LYR):-2.03

Loading ...

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

GlobeNewswire
·
Jun 04

Fate Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Jun 04

Fate Therapeutics grants 67,300 RSUs to two new hires under inducement plan

Reuters
·
Jun 03

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 03

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 03

Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo

Reuters
·
Jun 01

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

GlobeNewswire
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
May 27

CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

TIPRANKS
·
May 23

Top Fate Therapeutics Insiders Quietly Unload Shares in Back‑to‑Back Moves

TIPRANKS
·
May 22

Fate Therapeutics Announces Presentations at 2026 Asco and Eular Annual Meetings Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases

THOMSON REUTERS
·
May 21

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

GlobeNewswire
·
May 21

Fate Therapeutics assumed with a Buy at Jefferies

TIPRANKS
·
May 20

Wells Fargo Remains a Hold on Fate Therapeutics (FATE)

TIPRANKS
·
May 14

Fate Therapeutics reports Q1 EPS (26c), consensus (28c)

TIPRANKS
·
May 13

Fate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028

Reuters
·
May 13

Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate

Benzinga Earnings
·
May 13

Fate Therapeutics Q1 FY26 net loss narrows 17.04% to $31.21 million

Reuters
·
May 13

Fate Therapeutics Q1 Operating Expenses USD 34.299 Million

THOMSON REUTERS
·
May 13